Alnylam Pharmaceuticals (NASDAQ:ALNY) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a report issued on Saturday morning.

ALNY has been the topic of a number of other reports. Royal Bank of Canada reaffirmed an outperform rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. JPMorgan Chase & Co. lifted their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a neutral rating in a report on Thursday, February 1st. BMO Capital Markets reaffirmed an outperform rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. HC Wainwright reiterated a buy rating and set a $395.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Finally, The Goldman Sachs Group cut Alnylam Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $216.12.

Alnylam Pharmaceuticals Stock Down 0.5 %

Shares of ALNY stock opened at $147.70 on Friday. The company has a market cap of $18.60 billion, a price-to-earnings ratio of -41.49 and a beta of 0.39. Alnylam Pharmaceuticals has a 52 week low of $143.52 and a 52 week high of $218.88. The firm has a 50 day moving average of $153.53 and a 200-day moving average of $167.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. During the same period in the previous year, the business posted ($1.68) EPS. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals will post -4.54 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Quent Capital LLC increased its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 123 shares during the last quarter. KB Financial Partners LLC bought a new position in Alnylam Pharmaceuticals during the first quarter valued at $35,000. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $38,000. GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $52,000. Finally, V Square Quantitative Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $52,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.